RecruitingNot Applicable

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Canada500 participantsStarted 2015-03-12

Plain-language summary

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Who can participate

Age range15 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma Exclusion Criteria: * Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy

What they're measuring

Malignant Transformation Rate: Dysplasia

Timeframe: 60 months

Trial details

NCT IDNCT04622462

SponsorProteocyte Diagnostics Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-12-31

Contact for this trial

Jason Hwang, PhD

(647) 255-1370 jhwang@proteocyte.com

View on ClinicalTrials.gov More Oral Neoplasm trials